Amgen, already under a recommendation of added warnings for its anemia drugs, faces possible new competition from a Roche anemia drug. Federal regulators are scheduled to decide this week on preliminary approval for Roche's Mircera, which also uses a biotech protein to increase red blood cell production.

Full Story:

Related Summaries